Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -2.3% 10.60 10.50 10.70 10.85 10.60 10.85 498,679 09:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 68.3 -6.9 -1.3 - 68

Allergy Therapeutics PLC Trading update

11/07/2019 7:00am

UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Allergy Therapeutics Charts.


RNS Number : 1592F

Allergy Therapeutics PLC

11 July 2019

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Trading update

   -     Earnings ahead of market expectations and market share continues to grow 

- First meeting with regulatory authorities to prepare first in human trial for peanut allergy product

11 July 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.


As previously announced, the Group now expects earnings for the full year 2019 to be ahead of market expectations. Net revenue is expected to be GBP73.7m (2018: GBP68.3m) representing 8% annual growth on a reported and constant currency basis reflective of strong performance. The Group is continuing to gain market share within its core markets in Europe and data for the key markets for the 12 months ending 31 March 2019 showed a 0.6 market share point increase(1) . Overheads are expected to be in line with market expectations.

The cash balance at the end of June 2019 was GBP27.4m (30 June 2018: GBP15.5m) which includes $7.6m (GBP6m) received before year end in settlement of litigation against Inflamax and three of its senior employees regarding a clinical trial, which ATL alleged was poorly run by Inflamax, as announced on 28 June 2019.

On current assumptions, the Group will be able to fund the Grass MATA MPL Phase III trial currently planned to start in autumn 2020 from existing resources. If the trial is successful, and subject to completion of the safety database, the Group will pursue regulatory filing in the US, opening up a potential market of approximately $2 billion.


In addition to the continued progress of its European business, the Group is exploring the potential distribution of its products in other markets, including China, and will provide an update when further information is available.


The Group had a good meeting with Swissmedic, the Swiss regulatory authority, to discuss the potential protocol for the first in human trial of its VLP-based (Virus-like Particle) Peanut product, due to start in H1 2020, and also continues to make good progress with the commercial scale-up process for this product. The Group is also looking to expand the VLP technology into other allergy areas.

Manuel Llobet, CEO at Allergy Therapeutics, stated: "Our strong, technically advanced and convenient product portfolio continues to perform well in the market and has facilitated 20 years of strong revenue growth. It is a testament to our patient-focused strategy that we continued to increase market share this year. We have made further progress on the pipeline portfolio and the Group's meeting with the Swiss regulatory authorities was an important milestone in the development of our exciting peanut product."

(1) Market data and internal estimates for 12 months to 31 March 2019, for the markets in which Allergy Therapeutics operates excluding Switzerland (competitor data not available)

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

July 11, 2019 02:00 ET (06:00 GMT)

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191120 17:06:16